Substantia nigra cells (SN)

The substantia nigra is a vital midbrain structure within the basal ganglia that is essential for motor coordination and reward-related behaviors (Wikipedia, 2024). It is divided into the pars compacta (SNc), which contains dopaminergic neurons, and the pars reticulata (SNr), which contains GABAergic neurons. The SNc neurons project to the striatum, and their loss is the defining pathological feature of Parkinson's disease, leading to motor deficits like bradykinesia and tremors (NIH, 2024). Because these cells are the primary source of dopamine in the nigrostriatal pathway, they are the focus of symptomatic treatments that aim to restore dopaminergic signaling (StatPearls, 2023). While current drugs effectively manage symptoms by increasing dopamine availability or activity, they do not prevent the continued death of these cells, which remains a major challenge in neurotherapeutics.

Other names

Substantia nigra pars compactaSNcSubstantia nigra pars reticulataSNrDopaminergic neurons of the substantia nigraBlack substance

Pharmacological agents targeting the dysfunction of these cells primarily act by replenishing dopamine levels (e.g., Levodopa), mimicking dopamine at its receptors (e.g., dopamine agonists), or inhibiting the enzymes responsible for dopamine degradation, such as MAO-B and COMT (StatPearls, 2023; NIH, 2024).